Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data
MedCity News
Monday, December 30, 2024 - 10:54pm
tags:
Axsome Therapeutics, Alzheimer's agitation, FDA, Auvelity
Boston Scientific Issues Recall for Accolade Pacemakers Linked to 2 Deaths
Xtalks
Monday, December 30, 2024 - 10:52pm
tags:
Boston Scientific, medtehc, Accolade, pacemakers, device recalls, patient deaths
Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal
MSN/Reuters
Monday, December 30, 2024 - 10:50pm
tags:
Sangamo Therapeutics, Pfizer, hemophilia A, gene therapy, giroctocogene fitelparvovec
2025 forecast: What can AstraZeneca's China probes teach other biopharma companies?
Fierce Pharma
Monday, December 30, 2024 - 10:48pm
tags:
AstraZeneca, China
Novo’s next-gen obesity drug misses expectations in closely watched trial
BioPharma Dive
Friday, December 20, 2024 - 11:34am
tags:
Novo Nordisk, CagriSema, clinical trials, weight loss
Phase III MASH miss sends Galectin stock tumbling
BioSpace
Friday, December 20, 2024 - 11:30am
tags:
Galectin, clinical trials, MASH, belapectin
Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision
Fierce Biotech
Friday, December 20, 2024 - 11:26am
tags:
Cytokinetics, Sanofi, China, aficamten, heart disease, Corxel Pharmaceuticals
GSK posts mixed survival data for Jemperli/Zejula combo in first-line ovarian cancer
BioSpace
Friday, December 20, 2024 - 11:24am
tags:
GSK, Jemperli, Zejula, clinical trials, ovarian cancer
Idorsia's sale of Tryvio falls behind schedule, but layoffs remain on track
Fierce Biotech
Friday, December 20, 2024 - 11:22am
tags:
Idorsia, hypertension, Tryvio, layoffs
Boston Scientific updates cryoablation catheter instructions after 4 death reports
Medtech Dive
Friday, December 20, 2024 - 11:22am
tags:
Medtech, Boston Scientific, esophageal injury, cryoablation
Why the drug industry and its friends are holding their fire on RFK Jr.
Axios
Friday, December 20, 2024 - 11:20am
tags:
pharma industry, Robert F Kennedy Jr., Donald Trump, vaccines
Sorriso Pharma’s UC treatment hits Phase Ib endpoints
Clinical Trials Arena
Friday, December 20, 2024 - 11:18am
tags:
Sorriso Pharma, ulcerative colitis, clinical trials, SOR102
Neuralink rival Precision raises $102m, and other financings
Pharmaphorum
Friday, December 20, 2024 - 11:09am
tags:
Precision Neurosciences, funding, Neuralink, brain-computer interfaces
Apollomics, after giving up on GlycoMimetics' leukemia therapy, posts drug's latest phase 3 fail
Fierce Biotech
Friday, December 20, 2024 - 11:08am
tags:
Apollomics, China, AML, uproleselan
Zepbound, Mounjaro shortages are resolved, FDA confirms
BioPharma Dive
Thursday, December 19, 2024 - 9:36pm
tags:
FDA, Eli Lilly, Zepbound, Mounjaro, drug shortages
FDA rejects Zealand Pharma's GLP-2 analog in rare bowel disease
Fierce Biotech
Thursday, December 19, 2024 - 9:29pm
tags:
Zealand Pharma, glepaglutide, FDA, short bowel syndrome
Ionis Pharma's TRYNGOLZA Receives FDA Approval For Genetic Disorder Treatment
NASDAQ
Thursday, December 19, 2024 - 9:26pm
tags:
Ionis Pharmaceuticals, FDA, Tryngolza, hypertriglyceridemia
A venture firm breathes new life into an old NGM drug
BioPharma Dive
Thursday, December 19, 2024 - 9:23pm
tags:
KdT Ventures, NGM Biopharmaceuticals, NGM313
Medtech M&A Picked Up in 2024, But Belt-Tightening Continues
Medical Devices and Diagnostics Industry
Thursday, December 19, 2024 - 9:19pm
tags:
Medtech, M&A
Xcovery wins FDA approval for ALK inhibitor in NSCLC
First Word Pharma
Thursday, December 19, 2024 - 9:18pm
tags:
Xcovery, FDA, Ensacove, ALK inhibitors, non-small cell lung cancer

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.